He studied Business Administration at the Faculty of Economics “Richard M. Goodwin” in Siena, earning his Bachelor’s Degree with a thesis on International Accounting, research theme on methodological aspects and problems of the adoption of IAS / IFRS Accounting Standards for SMEs. While studying Management and Governance at the Department of Business and Legal Studies at the University of Siena, he gained experience on the field in a Business Consultant Studio. He obtained his Master’s Degree with a graduation thesis on the business model that characterizes the start-up phase of companies in the Life Sciences cluster. He has been working in VisMederi since March 2014, dealing with Corporate Finance and Management Control. From January 2015 to June 2016, he became a member of the company’s Board of Directors. Since April 2016, he is the Head of the Corporate Finance Area of VisMederi.

Alessandro graduated in Biology obtaining his bachelor’s degree in 2009 and a Master’s Degree in Molecular Evolution in 2013 at the University of Siena. He worked for six months in a big company in the field of Life Sciences. In November 2013, he won a competition for PhD students in Biochemistry and Molecular Biology at the University of Siena. In the first year, he worked on a project of Influenza Micro-Neutralization and Viral Growth in various cell lines. In the summer of 2015, he spent five months at the Influenza Centre in Bergen, Norway, under the direction of Professor Rebecca Jane Cox, studying the field of validation of new serological assays for IgA and IgG detection. From 2016 to 2020 he worked as a Project Leader in VisMederi Research managing a research group involved in the set-up and standardization of new serological assays for different infectious diseases including the new SARS-CoV-2 pandemic strain. He is currently working as a Project Director in VisMederi managing clinical trial studies and research collaborations with private and public Italian organizations.

Simonetta Viviani is an independent consultant in vaccines, epidemiology and public health. She collaborates with the Institut National de la Santé et de la Recherche Médical (INSERM) Marseille, France; International Vaccine Institute, Seoul, South Korea; PATH Seattle, USA; the Novartis Vaccines Institute for Global Health (NVGH), Siena, Italy; Takeda Vaccines Zurich, Switzerland; BionetAsia, Bangkog, Thailand. From October 2010 to December 2012 she was Associate VP, Head of the Dengue Clinical Development Program at Sanofi Pasteur. The program which includes large efficacy trials in endemic areas, is in clinical phase IIb/III, and aims to license the first tetravalent live attenuated Dengue vaccine for the prevention of dengue disease. From March 2005 to September 2011, she was Director of Vaccine Development at the Meningitis Vaccine Project (MVP). Created in 2001 with core funding from the Bill & Melinda Gates Foundation, its goal is to eliminate epidemic meningitis in Sub-Saharan Africa through the development and wide spread use of meningococcal conjugate vaccines. In June 2010, a meningococcal A vaccine –MenAfriVac- was prequalified by WHO. Dr Viviani has extensive experience in public health, infectious diseases epidemiology, clinical research, and vaccine development. From September 2002 to February 2005, she has served as clinical research and medical affairs manager for combined pediatric vaccines (DTPHibHBV, MMR) ,Flu and HIV vaccines, at Berna Biotech in Bern, Switzerland, and as medical director at Etna Biotech (Berna Biotech Group) in Catania, Italy. From 1997 to 2002, she was associate director of the clinical research department at Chiron Vaccines in Siena, Italy, where she was in charge of Hib, Hib combined, and meningococcal conjugate vaccines. From 1995 to 1997 she served at the International Agency for Research on Cancer (a WHO agency) as an epidemiologist attached to The Gambia Hepatitis Intervention Study, a large intervention trial aimed to prevent infection, chronic carriage and primary liver cancer in a high risk population by extensive vaccination with Hepatitis B vaccine. Dr Viviani has been a consultant in public health and epidemiology for the Department of Public Health in Florence, Italy, and has collaborated with the Istituto Superiore di Sanità, Rome, Italy on surveillance of communicable and vaccine preventable diseases. She has worked in Public Health and Epidemiology projects in Zimbabwe, Brazil and Guinea Bissau. She has also experience as a family doctor in the rural areas of Tuscany, Italy. Dr. Viviani received a Medicine and Surgery Degree from University of Siena, Italy, as well as postgraduate degrees in Public Health and Laboratory Research. She holds a two-year postgraduate training degree in Field Epidemiology from the CDC, Atlanta, USA, and the Istituto Superiore di Sanità, Rome, Italy. She has served as advisor for the International Agency for Research on Cancer, for the Initiative for Vaccine Research Department at WHO, Geneva, for MSF, Access to Essential Medicines Campaign, Geneva. She has published in the field of public health, epidemiology and vaccinology.

Sue Ann is Professor of Global Health, Vaccinology and Paediatric Infectious Diseases at University of Oxford and University of Siena, where she is the Head of the Institute for Global Health. Sue Ann is senior consultant for the Bill and Melinda Gates Foundation since 2012. In over 25 years of experience, she has contributed to the development of more than 20 globally licensed vaccines and pharmaceutical products. Vaccines she has worked on have saved millions of lives worldwide and reduced long term sequelae and disabilities, contributing to global health which is one of her key missions and goals. Sue Ann was part of the development of the first vaccine that gained emergency use listing by WHO, the new oral type 2 polio vaccine. Sue Ann is one of the Principal Investigators of the Oxford/AstraZeneca vaccine clinical development and was part of the development of 2 other COVID-19 vaccines. Sue Ann was knighted Commander of the Order of the British Empire, CBE, for services to Sciences and Public Health in 2021, by Queen Elizabeth II, she is also knighted Commander of order of Rio Branco and Medical Merit of the Federal Republic of Brazil.

Sue Ann has also been contributing to teaching and capacity building in different areas and created the first Master in Vaccinology and Drug Development worldwide at the University of Siena. And as founder and Director of GRID Europe, has the pleasure to be one of the sponsors of the Master program.

Emanuele Montomoli is Full Professor of Hygiene and Public Health at the University of Siena, Italy. He received his BSc and MSc in Life Sciences from the University of Siena, Italy in 1997 and he earned his MBiochem in 2001.
His research interests are primarily in the field of influenza vaccines, and in particular in the study of correlates of protection. He is an expert in the development, standardization and validation of assays for antibody detection. He has conducted many clinical and laboratory research studies to evaluate immunogenicity and efficacy of traditional and new influenza vaccines. Recently, he has participated in protocols for the development and evaluation of new molecules as adjuvants. He has also undertook planning and execution of European seroepidemiological studies for emerging infectious diseases in collaboration with WHO Regional Office and eCDC.
In 2012, he was appointed in the Scientific Advisory Board of international Society for Influenza and other Respiratory Viral Diseases (ISIRV).
In 2015, he became Scientific Coordinator for a European IMI (Innovative Medicine Initiative) Project titled “Standardization and development of assays for assessment of influenza vaccine correlates of protection (FLUCOP)” (IMI-JU-10-2013-01, Grant Agreement No 115672).
He has organized the 1st, 2nd and 3rd editions of the Summer School on Influenza in Siena with the support of ISIRV.
Over the years, he has published almost 70 scientific papers and reviews, and written several chapters in textbooks.
In VisMederi, he is in charge with the position of Chief Scientific Officer and not executive President.

Is Full Professor of Pediatric Infectious Diseases at the Department of Pediatrics at the Federal University of São Paulo, Brazil.  Since 1995 she has been the Coordinator of the Reference Center for Special Immunobiologicals at the Federal University of São Paulo-CRIE-Unifesp, a vaccination center aimed at high risk patients. She is a member of the Permanent Advisory Committee on Immunizations of the São Paulo State Department of Health and a member of the Technical Advisory Committee on Immunizations of the Ministry of Health, Brazil. Research lines in vaccinology: epidemiology of vaccine-preventable diseases, vaccination of risk groups, post-vaccination adverse events. She has conducted over 20 clinical trials on vaccines. She has edited two books on vaccines, 40 book chapters and 60 indexed scientific articles.

He studied Business Administration at the Faculty of Economics “Richard M. Goodwin” in Siena, earning his Bachelor’s Degree with a thesis on International Accounting, research theme on methodological aspects and problems of the adoption of IAS / IFRS Accounting Standards for SMEs. While studying Management and Governance at the Department of Business and Legal Studies at the University of Siena, he gained experience on the field in a Business Consultant Studio. He obtained his Master’s Degree with a graduation thesis on the business model that characterizes the start-up phase of companies in the Life Sciences cluster. He has been working in VisMederi since March 2014, dealing with Corporate Finance and Management Control. From January 2015 to June 2016, he became a member of the company’s Board of Directors. Since April 2016, he is the Head of the Corporate Finance Area of VisMederi.

In 2015, she graduated from the Faculty of Law with a thesis in Tax Law entitled “Tax Aspects of Reverse Merger. Analysis of a practical case.” The same year, after graduation, she carried out a five-month study experience in Australia and, just after this experience, she started working at a law firm in Siena. In 2018, she received her master’s degree Level II-CMU2 in Corporate Law from 24Ore Business School. In January 2019, she moved to Modena, where she worked at a law firm specializing in corporate law, before returning to Siena in March 2020. In the same month, she began working at VisMederi where she oversaw managing legal affairs, particularly the conclusion and review of contracts with international Sponsors. Since December 2021 she has joined VisMederi Holding where she manages the contractual relationships of all VisMederi Group companies.

After having obtained a scientific diploma in Siena, she attended the Faculty of Biological Sciences at the University of Siena. In October 2019, after taking part in the Erasmus program in Spain, she joined the pre-graduate curricular internship in the field of life sciences. In September 2021 she acquires the CELTA qualification for teaching English. During her studies she has participated in various training courses, including that relating to scientific writing.

After a period of teaching, since February 2022 she joined the company as Executive Programs Associate for the Institute of Global Health of the University of Siena and she is Executive Assitant for ETHS.